Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

Roche Holding ROP -1.01%decrease; red down pointing triangle said it agreed to buy PathAI for up to $1.05 billion in a deal that seeks to bolster the artificial-intelligence offerings of its diagnostics division.

The Swiss pharmaceutical group said Thursday that the acquisition of U.S.-based PathAI would build on a partnership between the two companies formed in 2021 and take in-house an AI platform that aims to facilitate diagnostic workflows and help accelerate clinical-therapy development.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8